Literature DB >> 9060973

Is metabolic evidence for vitamin B-12 and folate deficiency more frequent in elderly patients with Alzheimer's disease?

E Joosten1, E Lesaffre, R Riezler, V Ghekiere, L Dereymaeker, W Pelemans, E Dejaeger.   

Abstract

BACKGROUND: It is still unclear whether there is an association between Alzheimer's disease and vitamin B-12 or folate deficiency. This study was designed to investigate whether patients with Alzheimer's disease are particularly prone to metabolically significant cobalamin or folate deficiency as compared to nondemented hospitalized controls and healthy elderly controls living at home.
METHODS: Evaluation for the diagnosis of Alzheimer's disease, routine laboratory tests, serum folate and vitamin B-12, serum methylmalonic acid (MMA), total homocysteine (tHcy), and radiological tests was performed in 52 patients with Alzheimer's disease (AD), 50 nondemented hospitalized controls, and 49 healthy elderly subjects living at home.
RESULTS: Serum vitamin B-12 and folate levels are comparable between patients with AD, hospitalized control patients, and subjects living at home. Patients with AD have the highest serum MMA and tHcy levels. The MMA levels of patients with AD and hospitalized controls are not different, but the mean tHcy level is significantly higher in patients with AD as compared to nondemented patients or subjects living at home.
CONCLUSION: The interpretation of the vitamin B-12 and folate status in patients with AD depends largely on the methodology (i.e., serum vitamin vs metabolite levels) and the selection of the control group. Although patients with AD have the highest tHcy and MMA levels, metabolically significant vitamin B-12 and folate deficiency is also a substantial problem in nondemented elderly patients.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9060973     DOI: 10.1093/gerona/52a.2.m76

Source DB:  PubMed          Journal:  J Gerontol A Biol Sci Med Sci        ISSN: 1079-5006            Impact factor:   6.053


  15 in total

Review 1.  Prevention of Alzheimer's disease: where we stand.

Authors:  Mary Sano
Journal:  Curr Neurol Neurosci Rep       Date:  2002-09       Impact factor: 5.081

Review 2.  Is hyperhomocysteinemia an Alzheimer's disease (AD) risk factor, an AD marker, or neither?

Authors:  Jia-Min Zhuo; Hong Wang; Domenico Praticò
Journal:  Trends Pharmacol Sci       Date:  2011-06-20       Impact factor: 14.819

3.  Homocysteine and cognitive function in institutionalised elderly A cross-sectional analysis.

Authors:  M Manders; E Vasse; L C P G M de Groot; W A van Staveren; J G Bindels; H J Blom; W H L Hoefnagels
Journal:  Eur J Nutr       Date:  2005-08-04       Impact factor: 5.614

Review 4.  "Boomerang Neuropathology" of Late-Onset Alzheimer's Disease is Shrouded in Harmful "BDDS": Breathing, Diet, Drinking, and Sleep During Aging.

Authors:  Mak Adam Daulatzai
Journal:  Neurotox Res       Date:  2015-04-25       Impact factor: 3.911

5.  One-carbon metabolism and Alzheimer's disease: focus on epigenetics.

Authors:  Fabio Coppedè
Journal:  Curr Genomics       Date:  2010-06       Impact factor: 2.236

Review 6.  Psychological interventions for depression in adolescent and adult congenital heart disease.

Authors:  G Y H Lip; D A Lane; T A Millane; M H Tayebjee
Journal:  Cochrane Database Syst Rev       Date:  2003

7.  Cognitive impairment in folate-deficient rats corresponds to depleted brain phosphatidylcholine and is prevented by dietary methionine without lowering plasma homocysteine.

Authors:  Aron M Troen; Wei-Hsun Chao; Natalia A Crivello; Kristen E D'Anci; Barbara Shukitt-Hale; Don E Smith; Jacob Selhub; Irwin H Rosenberg
Journal:  J Nutr       Date:  2008-12       Impact factor: 4.798

8.  Homocysteine induces apoptosis of rat hippocampal neurons by inhibiting 14-3-3ε expression and activating calcineurin.

Authors:  Jing Wang; Xue Bai; Yongxing Chen; Yanxin Zhao; Xueyuan Liu
Journal:  PLoS One       Date:  2012-11-06       Impact factor: 3.240

9.  Homocysteine and cognitive impairment; a case series in a General Practice setting.

Authors:  Andrew McCaddon
Journal:  Nutr J       Date:  2006-02-15       Impact factor: 3.271

10.  NAT gene polymorphisms and susceptibility to Alzheimer's disease: identification of a novel NAT1 allelic variant.

Authors:  Nichola Johnson; Peter Bell; Vesna Jonovska; Marc Budge; Edith Sim
Journal:  BMC Med Genet       Date:  2004-03-17       Impact factor: 2.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.